NCT00046254已完成3 期
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2,127
- 试验地点
- 56
- 主要终点
- Significant reduction in rate of clinical fractures after surgical repair of hip fracture
研究概览
简要总结
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ages 50 years or older
- •Must have a recent hip fracture repair in the past 90 days
- •Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture
排除标准
- •Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Significant reduction in rate of clinical fractures after surgical repair of hip fracture
次要结局
- Increase in total hip and femoral neck BMDs
研究者
研究点 (56)
Loading locations...
相似试验
已完成
不适用
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate CancerOsteoporosisNCT00520052Wirral University Teaching Hospital NHS Trust58
已完成
4 期
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as BisphosphonatesProstate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is IndicatedNCT00172016Novartis Pharmaceuticals43
已完成
3 期
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving LetrozoleBreast CancerNCT00376740Soroka University Medical Center90
已完成
2 期
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate CancerBone LossProstate CancerNCT00181584Massachusetts General Hospital60
已完成
3 期
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral HeadAvascular Necrosis of Femoral HeadNCT00939900Seoul National University Bundang Hospital110